Annovis Bio, Inc.
ANVS
$2.67
$0.208.10%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.21% | -19.16% | -0.35% | 24.79% | 7.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.24% | -12.10% | -42.08% | -41.30% | -40.72% |
| Operating Income | -11.24% | 12.10% | 42.08% | 41.30% | 40.72% |
| Income Before Tax | -17.34% | 39.22% | 29.66% | 38.86% | 56.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.34% | 39.22% | 29.66% | 38.86% | 56.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.34% | 39.22% | 29.66% | 38.86% | 56.25% |
| EBIT | -11.24% | 12.10% | 42.08% | 41.30% | 40.72% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.46% | 61.91% | 53.89% | 57.10% | 68.27% |
| Normalized Basic EPS | 28.47% | 61.91% | 53.89% | 57.10% | 68.27% |
| EPS Diluted | 46.64% | 65.98% | 58.43% | 60.84% | 57.38% |
| Normalized Diluted EPS | 28.40% | 61.89% | 53.87% | 57.09% | 68.30% |
| Average Basic Shares Outstanding | 68.74% | 57.02% | 55.83% | 44.13% | 34.97% |
| Average Diluted Shares Outstanding | 68.05% | 56.32% | 55.07% | 43.39% | 35.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |